<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537575</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT-200700-3559-35</org_study_id>
    <nct_id>NCT01537575</nct_id>
  </id_info>
  <brief_title>Intravenous Immunoglobulins for Post-Polio Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Integrata Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Integrata Verona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postpolio syndrome is a condition that affects many polio survivors years after the acute
      infection and causes symptoms to increase or new symptoms to develop. Proinflammatory
      cytokine production within the central nervous system (CNS) indicates an underlying
      inflammatory process, amenable to immunomodulatory therapy. In this study the investigators
      sought to confirm that antiinflammatory treatment with intravenous immunoglobulin improves
      the disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SF-36 physical component</measure>
    <time_frame>Baseline; 2 and 4 months after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Post-polio Syndrome</condition>
  <arm_group>
    <arm_group_label>saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous immunoglobulins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intravenous immunoglobulins</intervention_name>
    <description>One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days</description>
    <arm_group_label>intravenous immunoglobulins</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a history of acute poliomyelitis

          -  increased muscle weakness, muscle fatigue and pain in muscle groups previously
             affected by poliomyelitis

          -  a diagnosis of postpolio syndrome according to the criteria of Halstead and Rossi

        Exclusion Criteria:

          -  clinically relevant systemic disease

          -  malignancy

          -  hypothyroidism

          -  diabetes mellitus not fully controlled by medical therapy

          -  medical or orthopedic disorders that could give rise to symptoms mimicking post-polio
             syndrome

          -  conditions associated with prolonged coagulation time

          -  serum IgA deficiency

          -  previous allergic reaction to IVIG

          -  body-mass index greater than 30

          -  immune-modulating treatments other than IVIG within the preceding 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2012</study_first_submitted>
  <study_first_submitted_qc>February 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <last_update_submitted>February 23, 2012</last_update_submitted>
  <last_update_submitted_qc>February 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria Integrata Verona</investigator_affiliation>
    <investigator_full_name>Laura Bertolasi</investigator_full_name>
    <investigator_title>Head of the Neurophysiology Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Postpoliomyelitis Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

